These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16848778)

  • 21. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.
    Kaveri SV; Dietrich G; Hurez V; Kazatchkine MD
    Clin Exp Immunol; 1991 Nov; 86(2):192-8. PubMed ID: 1934588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution].
    Galeotti C; Maddur MS; Kazatchkine MD; Mouthon L; Kaveri SV
    Transfus Clin Biol; 2009 May; 16(2):75-9. PubMed ID: 19443254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors.
    Kaneko Y; Nimmerjahn F; Madaio MP; Ravetch JV
    J Exp Med; 2006 Mar; 203(3):789-97. PubMed ID: 16520389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunoglobulin Fc receptors of streptococci and its relation to the virulence of the microbes].
    Burova LA; Ric M; Ermolenko EI
    Vestn Akad Med Nauk SSSR; 1986; (7):57-63. PubMed ID: 3529694
    [No Abstract]   [Full Text] [Related]  

  • 25. What is the contents of the magic draft IVIg?
    Seite JF; Shoenfeld Y; Youinou P; Hillion S
    Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro.
    Pollreisz A; Assinger A; Hacker S; Hoetzenecker K; Schmid W; Lang G; Wolfsberger M; Steinlechner B; Bielek E; Lalla E; Klepetko W; Volf I; Ankersmit HJ
    Br J Dermatol; 2008 Sep; 159(3):578-84. PubMed ID: 18565176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of anti-inflammatory activity of intravenous immunoglobulin via inhibitory Fcgamma receptors.
    Maródi L
    Pediatr Res; 2001 Nov; 50(5):551. PubMed ID: 11641444
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.
    Prabagar MG; Choi HJ; Park JY; Loh S; Kang YS
    Clin Exp Med; 2014 Nov; 14(4):361-73. PubMed ID: 23996469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intravenous immunoglobulin therapy is more and more common. The increasing tempo can force a prioritization of patients, scientists are warning].
    Orn P
    Lakartidningen; 1999 May; 96(18):2186-9. PubMed ID: 10377651
    [No Abstract]   [Full Text] [Related]  

  • 30. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antiinflammatory activity of IgG: the intravenous IgG paradox.
    Nimmerjahn F; Ravetch JV
    J Exp Med; 2007 Jan; 204(1):11-5. PubMed ID: 17227911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of sera from patients with rheumatoid arthritis on the availability of Fc receptor of the lymphocytes of normal subjects].
    Pazdur J; Nowaczyk M; Baczyńska K; Płachecka M
    Reumatologia; 1980; 18(2):151-6. PubMed ID: 6968963
    [No Abstract]   [Full Text] [Related]  

  • 33. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.
    Zandman-Goddard G; Blank M; Shoenfeld Y
    Lupus; 2009 Sep; 18(10):884-8. PubMed ID: 19671787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors.
    Martyn JC; Cardin AJ; Wines BD; Cendron A; Li S; Mackenzie J; Powell M; Gowans EJ
    Arch Virol; 2009; 154(7):1129-38. PubMed ID: 19557497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro.
    Stangel M; Schumacher HC; Ruprecht K; Boegner F; Marx P
    Immunol Invest; 1997; 26(5-7):569-78. PubMed ID: 9399100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fc receptors for IgE on macrophages and lymphocytes: IgE synthesis. Introduction.
    Spiegelberg HL
    Fed Proc; 1983 Jan; 42(1):122-3. PubMed ID: 6401248
    [No Abstract]   [Full Text] [Related]  

  • 37. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition.
    Basta M
    Mol Immunol; 2008 Oct; 45(16):4073-9. PubMed ID: 18706699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin therapy for autoimmune diseases.
    Arnson Y; Shoenfeld Y; Amital H
    Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications.
    Czajkowsky DM; Andersen JT; Fuchs A; Wilson TJ; Mekhaiel D; Colonna M; He J; Shao Z; Mitchell DA; Wu G; Dell A; Haslam S; Lloyd KA; Moore SC; Sandlie I; Blundell PA; Pleass RJ
    Sci Rep; 2015 Apr; 5():9526. PubMed ID: 25912958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction.
    Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Brenner T; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2008; 1132():244-8. PubMed ID: 18567875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.